Plinabulin is under clinical development by BeyondSpring and currently in Phase III for Metastatic Breast Cancer. According to GlobalData, Phase III drugs for Metastatic Breast Cancer have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Plinabulin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Plinabulin overview
plinabulin (NPI-2358) is under development for the treatment of non-small cell lung cancer (second and third line), metastatic breast cancer, chemotherapy-induced neutropenia and febrile neutropenia (second line), metastatic brain tumor, Merkle cell cancer , melanoma, small cell lung cancer, glioblastoma multiforme, cancer associated with a RAS mutation such as colorectal cancer, multiple myeloma, bladder cancer. The drug is administered as an intravenous infusion. It is is a halimide derivative. It is a new chemical entity and a synthetic analog of NPI-2350, a natural product isolated from Aspergillus species. It binds to the colchicine-binding site of beta tubulin and GEFH1. It was also under development for metastatic pancreatic cancer, advanced solid tumor malignancies or lymphoma.
See Also:
BeyondSpring overview
BeyondSpring is a clinical-stage biopharmaceutical company that develops immune-oncology cancer therapies. The company’s lead product candidate is Plinabulin, a selective immunomodulating microtubule-binding agent with potential chemotherapy-induced neutropenia (CIN) prevention and anti-cancer benefits. BeyondSpring other pipeline includes BPI-002, BPI-003 and BPI-004 for the treatment of various cancers and tumors. The company collaborates with Fred Hutchinson Cancer Center, University of California San Diego, Johns Hopkins University, Rutgers University and the University of Basel, among others. It operates through subsidiaries in the US, Hong Kong, China, the UK, Australia and Brazil . BeyondSpring is headquartered in New York, the US.
For a complete picture of Plinabulin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
